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Abstract
CD97 is over-expressed in the majority of gastric adenocarcinomas and is associated with its dedifferentiation and
aggressiveness. Our previous results demonstrated that out of three CD97 isoforms tested, only the small one was able to
promote increased invasiveness in vitro. Based on these data we further aimed to investigate the role of CD97 small isoform
in gastric cancer progression in vivo by employing the cells with a stable CD97 small isoform knock-down and an orthotopic
gastric cancer mouse model. We could demonstrate that the knock down of CD97/EGF1,2,5, led to a significant decrease in
the number of cells penetrating the gelatin coated membrane as compared with control cells. In the gastric cancer mouse
model, both the hypodermic and the orthotopic yielded tumor masses of the CD97/EGF1,2,5kd group and were significantly
smaller than the control. Metastatic tumor cell number in early metastatic regional lymph nodes on post-operative day 42
was distinctly decreased in the CD97/EGF1,2,5kd group as compared with the SGC-NS group, and was accompanied with
the downregulation of CD44, VEGFR, CD31 and CD97. We concluded in this study that CD97 small isoform not only
supported gastric cancer local growth, but also promoted metastatic spread in orthotopically implanted mouse model
suggesting involvement of the CD97 small isoform in the preparation of (pre)metastatic niche.
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Introduction
CD97 is a member of a new subgroup of seven-span
transmembrane (TM7) molecules which belong to the secretin
receptor superfamily [1–3]. CD97 is produced as alternatively
spliced forms that contain three (EGF1,2,5), four (EGF1,2,3,5), or
five (EGF1-5) repeated EGF-like domains which mediate binding
to its cellular ligand, decay accelerating factor (DAF, CD55), a
regulatory protein of the complement cascade [4–6]. CD97 was
originally found to be expressed by hematopoietic cells [7,8], then
abundantly detected in various normal tissues and advanced stages
of thyroid, colorectal, gastric, pancreatic, esophageal and oral
squamous cell carcinomas [9–14]. CD97 protein is over-expressed
in majority of gastric adenocarcinomas (60%–88%) and mostly
located in the tumor cells at the invasion front, which has higher
motility as compared to the cells in the solid formation [15,16].
Various studies reported that elevated expression of CD97 in
gastric cancer is associated with the dedifferentiation and
aggressiveness of tumor cells and directly correlates with clinico-
pathological parameters such as TNM classification [14,16].
Recently, the interaction between the small isoform of CD97
(CD97/EGF1,2,5) and its ligand CD55 led to increased motility
and elevated proteolytic activity of matrix metalloproteinases or
chemokine secretion was revealed in colorectal cancer cells
[17,18].
Our previous studies revealed that out of three CD97 isoforms,
only the small one was associated with increased invasive behavior
of gastric cancer cells in vitro [19]. However, knowledge of the role
of CD97 isoforms, especially CD97/EGF1,2,5, in tumor metas-
tasis in vivo is still lacking.
In this study, by employing the cells with stable CD97 small
isoform knock-down and orthotopic gastric cancer mouse model,
we further investigated the role of CD97 small isoform in gastric
cancer progression in vivo, focusing on tumor development and
metastatic potential.
Results
Generation of Transfectants with Stable Knockdown of
CD97 Small Isoform
For this purpose, four human gastric cancer cell lines, SGC-
7901, AGS, BGC-823 and MGC-801 were investigated for the
CD97 gene expression. RT-PCR revealed that all cell lines
investigated expressed CD97, however with different isoform
distribution (EGF1,2,5; EGF1,2,3,5 and EGF1-5) (Figure 1A). As
demonstrated before [19], BGC-823 cells had the lowest intensity
of CD97/EGF1,2,5 but the strongest intensity of CD97/EGF1-5,
while AGS showed the strongest expression of CD97 small isoform
but the weakest of CD97 big isoform. SGC-7901 which expressed
moderate levels of both CD97 small and big isoforms was selected
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D). After we transfected SGCwt cells with shRNAs targeting four
different sites of CD97/EGF1,2,5 and selected stable clones by
G418, the expression of CD97 small isoform was evaluated by
RT-PCR and western blot. As compared with wild-type cells or
the clones bearing non-silencing shRNAs, the clones expressing
the forth shRNA (CD97iso3-Si4) displayed a 40% loss of CD97/
EGF1,2,5 mRNA expression (Figure 1E) and a nearly total loss of
CD97 protein (,80 kDa) (Figure 1F). The silencing of CD97/
EGF1,2,5 by employing other sh-RNA site induced similar
reduction and effects as compared to CD97iso3-Si4. It is worth
to note that due to the knock-down of CD97/EGF1,2,5, the other
two isoforms (CD97/EGF1,2,3,5 and CD97/EGF1-5) were not
significantly affected.
Effect of CD97 Small Isoform on Proliferation, Migration
and Invasion of Human Gastric Cancer Cells
Increased proliferation and migration are both important
parameters defining cancer cells and their reductions may serve
as potential anti-cancer therapy. In this study, the proliferative
ability of CD97/EGF1,2,5 kd clones was significantly higher as
compared to the wild-type and control groups, which coincided
with our previous research (Figure 2B). Using the scratch-wound
assay, a continuous movement was observed in all the three
groups, but a more significant movement of the CD97/
EGF1,2,5 kd clones migration front was evident at 24 h, in which
the cell-free ‘‘scratch’’ region was almost full confluent. Upon
comparison with wild-type and empty control groups, the
migration of CD97/EGF1,2,5 kd clones was significantly en-
hanced after 24 h of incubation (P,0.01) (Figure 2A, 2D). These
observations revealed that the down regulation of CD97 small
isoform did not result in an inhibition of proliferative or migrative
ability of gastric cancer cells as previously expected, but caused a
statistical significant enhancement of both the proliferative and
migrative ability of SGC-7901 cells.
Soft agar colony formation assay revealed the different invasive
ability of CD97/EGF1,2,5 kd clones. CD97/EGF1,2,5 kd clones
generated 5 times less colonies as compared with wild-type and
empty control cells. Furthermore, the colonies formed by CD97/
EGF1,2,5 kd clones were bigger in size and showed the preference
of aggregated growth rather than the pattern of detachment from
the main tumor bulk and disseminated growth (Figure 2C). To
confirm whether CD97 small isoform may affect the extracellular
matrix by alterations of penetrating ability, transfectants investi-
gated were seeded on filters coated with gelatin. After 24-h
incubation in the upper chamber, the cells that had migrated to
the other side of the filter were stained and counted. The number
of penetrated CD97/EGF1,2,5 kd clones was significantly de-
creased when compared with empty control, which indicated its
partial loss of invasive ability after the knock down of CD97 small
isoform (Figure 2E,2F).
CD97 Small Isoform Supports Gastric Cancer Local
Growth
Aiming at verifying the invasion promoting role of CD97 small
isoform in vivo, a mouse orthotopic gastric cancer model with a
high frequency of lymph node metastasis was employed. Six-eight
weeks after the hypodermic inoculation of SGC wt, SGC-NS and
CD97/EGF1,2,5 kd clones, 100% of gastric cancer cells (10/10)
grew as subcutaneous implants in nude mice. The size of
subcutaneous formed tumor masses of the SGC wt
(1.0560.3 cm) and SGC-NS (1.0160.2 cm) groups were signifi-
cantly bigger than the CD97/EGF1,2,5 kd group (0.460.05 cm)
as indicated in Figure 3A and no regional or distant metastasis was
observed. Hypodermic tumor masses were harvested and ortho-
topically transplanted as described. Primary tumor masses and
metastases which included local and distant lymph nodes, the liver,
the lung and the pancreas were weighted and harvested on post-
operative days 7–42 and histologically confirmed. Similar with the
hypodermic yielded tumor masses, the weight of primary tumor
masses of CD97/EGF1,2,5 kd group (0.660.14 g) were signifi-
cantly lower as compared to SGC wt (2.860.26 g) and SGC-NS
(2.660.28 g) groups on post operative days 42, which again
suggested the tumor supporting effect of CD97 small isoform
(Figure 3B).
CD97 Small Isoform Supports Metastatic Spread of
Orthotopically Implanted Gastric Cancer
To further evaluate the role of CD97 small isoform in lymph
node metastasis, metastatic tumor cells within lymph nodes along
the lesser gastric curvature were counted by C4.4A staining and
flow cytometry (Figure 3C). Though only small amount of tumor
cells were detected on post operative days 7 (2–361610
4/LN), the
frequency of lymph node metastasis was 100% (60/60). The tumor
cell number within CD97/EGF1,2,5 kd group (69610610
4/LN)
was distinctly decreased on post operative days 42 as compared to
SGC wt (250631610
4/LN) and SGC-NS (268625610
4/LN)
groups.
Further investigations were performed on EPCAM, VEGFR
and CD44, tetraspanins and integrins previously reported to
participate in tumor progression by preparation of (pre)metastatic
niche. In this study, CD44, VEGFR, CD31 together with CD97
antibodies were employed to examine the metastasis-supporting
effect of CD97 small isoform and the alterations of transmem-
brane receptors protein expression by down regulation of CD97/
EGF1,2,5. Strongly down regulated CD44, VEGFR, CD31, as
well as CD97 expression in early metastatic regional lymph nodes
(lymph nodes along the lesser gastric curvature of post-operative
day 7) of CD97/EGF1,2,5 kd group were demonstrated by
immunohistochemistry, which indicated the potential involvement
of CD97 in the preparation of (pre)metastatic niche (Figure 3D).
Discussion
Previous studies demonstrated that CD97 isoforms play dual
roles in gastric cancer cell migration and invasion, and only the
CD97 small isoform is associated with increased invasive behavior
of gastric cancer. To verify this theory, we generated stable
knockdown clones of CD97 small isoform and established
orthotopic gastric cancer mouse model with metastasis. We found
in this study CD97 small isoform not only supported gastric cancer
local growth, but also promoted metastatic spread in orthotopi-
cally implanted mouse model. Involvement of the CD97 small
isoform in the preparation of (pre)metastatic niche could be one of
the reasons.
It had been shown that CD97 protein was over-expressed in
tumor tissues, especially in scattered tumor cells at the tumor
invasion front, possessing much higher motile abilities than the
tumor cells in the solid formation [20,21]. Our previous studies
revealed that strong co-expressions of CD97 and its ligand CD55
were exclusively localized at the tumor invasion front of gastric
cancer, and additionaly correlated with its TNM status [14,16].
These findings further support the participation of CD97 in gastric
cancer cell migration and invasion. However, no relations with
lymph node metastasis or lymphoid/blood vessel infiltration were
found by clinicopathological investigations [15].
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EGF1,2,5 or CD97/EGF1-5 in low CD97 cell line BGC-823
triggered the mechanisms resulting in quite different cell
behaviours. The cells bearing CD97/EGF1,2,5 insert revealed
increased invasive behavior, while the cells over-expressing
CD97/EGF1-5 long isoform demonstrated tumor suppressive
properties [19]. Other investigations concering CD97 variants
revealed that over-expression of CD97/EGF1,2,5 insert propa-
gated invasion of colon cancer cells, while C-terminal insertion
reduced it. Besides, the motility of the cells remained almost
unaffected when the full length isoform was over-expressed [17],
what is with agreement to our findings. Thus, the CD97-induced
augmentation of cancer invasiveness is closely related to its small
isoform. Based on these observations and our previous findings, we
focused further investigations on the specific role of CD97 small
isoform in gastric carcinoma progression and metastasis.
SGC-7901 cells which expressed moderate levels of both CD97
small and big isoforms were selected as a suitable model to
investigate the specific effects of CD97 small isoform. After knock-
down of CD97/EGF1,2,5, the proliferative ability of CD97/
EGF1,2,5 kd clones was significantly higher as compared to the
wild-type or control groups, while the invasive ability was
dramatically decreased. It conformed to our previous research
that CD97 small isoform is associated with the invasive behavior,
Figure 1. Generation of transfectants with stable knockdown of CD97 small isoform. (A) CD97 expression on gastric carcinoma cell lines
SGC-7901, AGS, BGC-823 and MGC-801. (B) Expression of CD97 isoforms in SGCwt, SGC-NS and CD97/EGF1,2,5 knockdown groups. Semi-quantitative
RT-PCR analysis, performed with the Bio 1D software, revealed differentially expressed (C) CD97 small and (D) big isoforms of the four cell lines, and
significantly decreased levels of (E) CD97 small isoforms in CD97/EGF1,2,5 knockdown group as compared with corresponding controls (*p,0.01). (F)
The ,85 kDa CD97 protein was detected by Western blot analysis in total cellular extracts of SGCwt cells, SGC-NS and CD97/EGF1,2,5 knockdown
transfectants.
doi:10.1371/journal.pone.0039989.g001
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proliferative property; and there existed an intrinsic balance
between the two isoforms, when the expression of one isoform
elevated, the other decreased. The elevation of the gelatinolytic
abilities of CD97/EGF1,2,5 kd clones was considered due to the
alternation of activity of MMPs. Galle J [17] reported HT1080
cells which over-expressing CD97 small isoform possessed the
highest activity of matrix metalloproteinases (MMPs) MMP-2 and
MMP-9, but HT1080 cells over-expressing CD97 full length
isoform responded with almost unaltered or even decreased levels
of MMPs as compared with wild-type or empty plasmid cells.
Although multivariate analysis reported no significant relations
between CD97 expression and lymph node metastasis, results in
this study showed noticeably retarded primary tumor growth as
well as fewer metastatic tumor cells in regional lymph nodes in
CD97/EGF1,2,5 kd group of the orthotopically transplanted
metastatic mouse model of gastric carcinoma. This phenomenon
conformed to the tumor invasive promoting role of CD97 small
isoform. But how can CD97 small isoform facilitate lymph node
metastasis?
In recent years, developed evidence based on Stephen Paget’s
‘‘seed and soil’’ hypothesis has emerged. Growth factors secreted
by the primary tumor prime certain tissues for tumor cell
engraftment [22–25]. In response to these soluble factors, tumor
associated cells such as macrophages and haematopoietic progen-
itor cells cluster at some functional microenvironment, which is
also known as ‘‘metastatic niches’’ that supports metastatic tumor
cell maintenance and actively regulates cell proliferation and
invasion [26–28]. This microenvironment is considered to
comprise supportive stromal cells, soluble factors, vascular
networks, nutrients and metabolic components, and the structural
extracellular matrix (ECM) architecture [29–31].
VEGF, critical regulator of tumor angiogenesis, is thought to
mobilize the bone marrow derived cells (BMDCs), which may
Figure 2. Effect of CD97 small isoform on proliferation, migration and invasion of human gastric cancer cells. The migration ability of
SGCwt cells, SGC-NS and CD97/EGF1,2,5 groups were assessed by scratch-wound assay (A) and soft agar (C), which showed bigger size colonies and
aggregated type of growth. The migration rate (D) was calculated as the proportion of the mean distance between both borderlines caused by
scratching to the distance that remained cell-free after re-growing (*p,0.01). (B) MTT assay revealed the proliferative ability was significantly higher
in CD97/EGF1,2,5 kd group as compared to the controls (*p,0.01). (E,F) Invasive assay revealed the number of penetrated CD97 small isoform kd
clones was significantly decreased as compared to the control (*p,0.01).
doi:10.1371/journal.pone.0039989.g002
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metastasis 888. It was reported that BMDCs express VEGFR
localized to pre-metastatic sites before the arrival of tumor cells,
and inhibition of VEGFR1 could prevent the BMDCs infiltration
and ‘‘metastatic niche’’ formation in lungs [32,33]. CD44 is also
known to be essential for the homing and engraftment of the
cancer stem cells [34–36]. It was reported after knocking down of
CD44v6, it failed to assemble a soluble matrix in pre-metastatic
organ, which allows a highly metastatic pancreatic cell line ASML
embedding and growth. It strongly indicated both VEGFR and
CD44 were involved in the preparation of (pre)metastatic niche
[37].
In this study, VEGFR, CD44 along with platelet endothelial cell
adhesion molecule (CD31) were together employed in an early
Figure 3. CD97 small isoform supports metastatic spread of orthotopically implanted gastric cancer. (A) The size of subcutaneous
formed tumor masses of CD97/EGF1,2,5 kd group was significantly smaller. (B) Primary tumor weight of orthotopically transplanted gastric cancer in
CD97/EGF1,2,5 kd group was significantly lighter (*p,0.01). (C) The metastatic tumor cells within regional lymph nodes were counted by C4.4A
staining and FACS (*p,0.01). (D) Immunohistochemistry: CD44, VEGFR, CD31 and CD97 expression in early metastatic regional lymph nodes of CD97/
EGF1,2,5 kd group were strongly down regulated.
doi:10.1371/journal.pone.0039989.g003
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caner to investigate the possible mechanism of the metastasis-
facilitating role of CD97 small isoform. In regional lymph nodes
along the lesser gastric curvature prior to metastasis, the control
group showed already existed, aggregated, high intensity of CD97
protein expression, as well as the elevated intensity of CD44,
VEGF and CD31 expression; while the CD97/EGF1,2,5 kd
clones showed comparatively scattered and down regulated
transmembrane receptors protein expression, which indicated
CD97 small isoform may also contribute to the metastasizing
tumor cells settlement and involved in the preparation of the
metastatic niche formation. However, information of how CD97
bearing tumor cells interacting with the metastatic organ
surroundings and how the long-distance communication estab-
lished is still lacking. Furthermore, it was reported the expression
of CD97 was consistently suppressed in glioblastoma cell lines
along with the silencing of WT1 [38], which suggested the possible
upregulation of CD97 and its invasiveness promotion role were
mediated by the regulation or expressional changes of other genes.
But there was very little data describing the regulatory relationship
of CD97 with other genes hitherto, which also merit further
investigation.
In summary, taking advantage of the establishment of
orthotopically transplanted metastatic mouse model of gastric
carcinoma and the knocking down clones of CD97/EGF1,2,5
which showed poor metastatic ability, we demonstrate CD97 small
isoform not only supports gastric cancer local growth, but also
facilitates metastasis in a mouse model. Involvement in the
preparation of the metastatic niche formation could be the reason
for the contribution of CD97 small isoform to the metastasizing
tumor cells settlement. Although exemplified in an animal model,
the findings in this study are required to be controlled for their
relevance in human cancer progression.
Materials and Methods
Cell Lines and Animals
All cell lines employed in this study were purchased from ATCC
(www.atcc.org). Stomach adenocarcinoma cell line SGC-7901,
MGC-801 and AGS cells were propagated in RPMI-1640
medium (Genom Biologic, Hangzhou); BGC-823 cells were
propagated in Dulbecco’s minimal essential medium (DMEM)/
Ham’s F12 (Genom Biologic, Hangzhou). All media were
supplemented with 10% fetal bovine serum (FBS, Gibco) and
1% penicillin/streptomycin (Genom Biologic). The cells were
grown in standard humidified incubator in 5% CO2 at 37uC and
passaged every 4–7 days using trypsin-EDTA.
All the animal studies were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and the
protocol was approved by the Animal Research Committee of
Zhejiang University, Hangzhou, China. All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering. Mouse protocols were conducted in
accordance with stringent regulations laid out by Zhejiang
University Laboratory Animal Center. Seventy-five 6–8-week old
male BALB/c nu/nu mice weighing 18–22 g used for subcuta-
neous (15/75) or orthotopic tumor implantation (60/75) were
randomly divided into control and CD97/EGF1,2,5 knockdown
groups. Animals were housed in a sterile environment, cages and
water were autoclaved, bedding and food was c-ray-sterilized. All
animals were maintained on daily 12-h light/12-h dark cycle,
which was controlled by qualified staff in the Zhejiang University
Laboratory Animal Center.
Knockdown of CD97 Isoforms by RNA Interference (RNAi)
Four RNAi candidate target sequences of human CD97 isoform
3 (CD97/EGF1,2,5) were designed following the procedure of
Dharmacon siDESIGN
TM center (Table 1), and were cloned into
pGCsilencer
TM U6/Neo/GFP vector (Shanghai GeneChem)
using Lipofectamine 2000 reagent according to manufacturer’s
protocol (Life Technologies). Selection of the clones was initiated 2
days after transfection by employing 700 mg/ml of G418. Two
weeks after transfection, positive clones were selected and
maintained in fresh medium containing G418 at final concentra-
tion of 500 mg/ml. Medium was changed every 2–3 days and
transfectants were passaged every 5–6 days. Expression of CD97
isoforms was verified by RT-PCR and Western blot analysis.
Nonsilencing (NS)-siRNA was used as a control.
Orthotopic Transplantation of Human Gastric Cancer
Subconfluent SGC-NS (control) and SGC-CD97/EGF1,2,5
RNAi clone cells were harvested with trypsin-EDTA and
resuspended to a final concentration of 1610
8/ml PBS.
Hypodermic inoculation: 0.1 ml of cell suspension was subcuta-
neously injected into the right flank of respective mouse. Six-
eight weeks later, when the size of tumor was around 1 cm
3,
tumor mass from each group was taken out and minced into
pieces of approximately 1 mm
3 for use in transplantation. Nude
mice were anesthetized with pentobarbital sodium solution
(Sinopharm Chemical Reagent, Beijing) via intraperitoneal
injection (45 mg/kg). A left lateral laparotomy was performed.
The stomach wall was carefully exposed, and a mechanical
serosal injury was made in the middle of the greater curvature.
One tumor piece was then fixed on the injured serosal surface
with a 5–0 Dexon transmural suture.
Evaluation of Growth and Metastasis of Orthotopically
Implanted Tumors
To evaluate the growth and metastasis of orthotopically
implanted tumors, mice were sacrificed according to the institu-
tional guidelines on postoperative days 7, 14, 28 and 42 before
they developed signs of distress. Autopsies were performed
immediately, and primary tumors growing on the stomach wall
were excised, weighed and examined histologically. The lungs,
liver and enlarged regional or metastatic lymph nodes in
peritoneal cavity were collected and processed for careful
immunohistochemical examination.
Total RNA Extraction and Reverse Transcriptase-
polymerase Chain Reaction (RT-PCR)
Total RNA from SGC-7901 wild-type cells (SGCwt), stable
SGC-NS and SGC-CD97/EGF1,2,5 RNAi clones was extracted
using TRIzol reagent according to manufacturer’s instructions
Table 1. RNAi candidate target sequences for CD97
isoform 3.
Sequence name Sequence (59-39)
Nonsilencing-siRNA TTCTCCGAACGTGTCACGT
CD97iso3-Si1 CCTGCATTCCAAGAAGCAA
CD97iso3-Si2 GCAGCTTTGCGATCCTTAT
CD97iso3-Si3 CATCCAGAATGTCATCAAA
CD97iso3-Si4 CTCAAACCTTGAAGATATC
doi:10.1371/journal.pone.0039989.t001
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CD97, specific intron-spanning oligonucleotide primers, which
are suitable for amplification of all 3 CD97 isoforms (sense-
actctgccgggagctgaaac; antisense-tggatggtgacctcggctga), were em-
ployed. RT-PCR reactions were performed in a 25-ml solution
containing 4 ml of cDNA, 2.5 mlo f1 0 6Advantage2 polymerase
mix buffer, 10 nmol/l of dNTP, 20 pmol of the primer, and 2 U
TaqDNA-polymerase (Life Technologies). PCR cycles consisted
of an initial denaturation step for 5 min at 95uC, followed by 35
cycles of denaturation at 94uC for 30 sec, annealing for 45 sec at
61uC, elongation for 45 sec at 72uC, and a final extension cycle
for 5 min at 72uC. PCR products were visualized on a 1%
agarose gel containing 0.05% ethidium bromide. Semiquantita-
tive RT-PCR analysis was performed with the Bio 1D software
(LTF, Wasserburg, Germany) and b-actin served as normalizing
marker.
Cell Proliferation Assay (MTT Assay)
SGCwt, stable SGC-NS and SGC-CD97/EGF1,2,5 RNAi
stable transfectants were plated in 200 ml of RPMI-1640 with 10%
FBS at 2.5610
4cells/well in 96-well plates. After overnight
incubation, the growth medium was replaced with serum-free
medium. At each time-point (24, 48 and 72 h), 20 ml of 5 mg/ml
MTT (Sigma) was added to each well and incubated at 37uC for
4 h to allow the reduction of MTT to formazan. Formazan
crystals were dissolved in 100 ml DMSO and measured at 540 nm
using ELISA reader (TECAN, Austria GmbH).
Scratch-wound Assay
Cells were seeded at 2610
5 cells/well in 6-well plates and
cultured as 70% confluent monolayers and deprived of serum for
24 h. A scratch was performed across the well with a standard
200 ml pipette tip and subsequently washed extensively with
RPMI-1640 (supplemented with 1% FBS). The rate of scratch
closure was determined by inverted phase contrast microscope
(Leica, Germany) immediately and 24 h later. The migration rate
was expressed as a percentage of the control (SGC-NS), and was
calculated as the proportion of the mean distance between both
borderlines caused by scratching to the distance that remained
cell-free after re-growing. Two independent series of experiments
were performed in quadruplicates.
Soft Agar Colony Formation
Two-layered soft agar assays were performed in 6-well plates.
The bottom layer of agar (1.5 ml per well) consisted of 2.5 ml of
3% agar (Roth) in sterile water, 1.5 ml of FBS, 150 ml of G418
(20 mg/ul), 150 ml of a 1:1,000 dilution of amphotericin B
(0.25 mg/ml; Sigma), and 450 ml of a 1:1,000 dilution of
gentamicin (10 mg/ml; Sigma) added to 15 ml with RPMI-1640
medium. Once solidified at room temperature for 10 min, 20,000
of SGCwt, SGC-NS and CD97/EGF1,2,5 RNAi clones were
separately mixed into 1 ml of upper agar layer prepared from a
stock consisting of 0.8 ml of 3% agar, 10% FBS, 75 ml of G418
(20 mg/ul), 75 ml (1:1,000 dilution) of amphotericin B, 225 ml
(1:1,000 dilution) of gentamicin in 15 ml of culture medium. This
cell suspension was carefully layered on the top of the bottom
layer. Once the top agar layer had solidified, 1 ml of the culture
medium was carefully added and changed once a week. After 4
weeks, cell colonies in the agar were stained overnight at 37uCi na
5% CO2 atmosphere with 200 ml of iodo-tetrazolium chloride
(5 mg/ml; Sigma). Stained cell colonies were examined by light
microscopy (Zeiss).
Invasion and Migration Assays
The invasion assays were evaluated in 24-well Transwell
TM
chambers (Costar). The upper and lower culture compartments
were separated by polycarbonate filters with 8 mm pore size. For
invasion assay, the upper site of the filters (upper chamber) was
coated with 1 mg/ml of gelatin (Sigma) before seeding the cells.
SGCwt, SGC-NS and CD97/EGF1,2,5 RNAi clones were seeded
at 2610
4cells/well in RPMI-1640 medium without FBS in the
upper chamber and the lower chamber was filled with medium
with 10% FBS. After 24-h incubation in a 5% CO2 atmosphere at
37uC, cells remaining on top of the filter were wiped off with
cotton swabs and those transfectants that had traversed the
membrane pores to the lower surface of the membrane were
washed with chilled PBS, incubated for 5 min in 1:1 PBS/
methanol and 15 min in methanol before staining with 0.1%
toluidine blue (Sigma) in 2.5% sodium carbonate. Migrated cells
were counted by light microscopy (Zeiss) in four separate high-
power fields per filter. For the migration assay, subconfluent
monolayer was scratched with a pipette tip. Wound healing was
evaluated after 24–72 h by light microscopy. All experiments were
performed at least in triplicates and were expressed as mean6
SEM.
Western Blot Analysis
CD97 protein expression was analyzed by western blot analysis.
SGCwt, SGC-NS and CD97/EGF1,2,5 RNAi clones were seeded
at 1.5610
5/well in 25 cm
2 flasks and cultured in medium with
10% FBS until 70% of confluency. Total proteins were isolated
with 26extraction buffer (125 mM Tris-HCl pH 6.8; 4% sodium
dodecylsulfate (SDS); 20% glycerol; 10% mercaptoethanol (ME);
2% bromophenol blue) plus protease inhibitors cocktail (all
reagents from Sigma). Proteins were resolved on a 12% SDS
gel, blotted at 1 mA/gel cm2 for 2 h onto Hybond-ECL
nitrocellulose membranes (Amersham). Membranes with blotted
proteins were blocked for 2.5 h with 5% milk in PBS plus 0.02%
Tween-20 (PBST; Sigma) and incubated overnight at 4uC with the
mouse polyclonal CD97 antibody (1:5,000; Abnova). Secondary
HRP-conjugated rabbit anti-mouse IgGs was used at 1:20,000 for
1 h at RT. Immunoreactive protein bands were visualized with the
ECL kit (Amersham). The same membranes were reprobed with
mAbs specific to human b-actin prior to incubation in stripping
solution (2% SDS; 125 mM Tris-HCl, pH 8.0; 0.7% ME) and the
block buffer (5% milk in PBS plus 0.02% Tween-20). b-actin was
visualized with secondary goat anti-mouse antibodies (Sigma,
1:20,000 in blocking buffer for 1 h) and ECL-kit.
Flow Cytometry
Lymph nodes (LN) aseptically removed were cut into small
pieces and meshed through fine gauze. Suspended cells (2–5610
5)
were stained with fluorochromeconjugated mAbs against C4.4A
(Santa Cruz Biotechnology) according to routine procedures. For
intracellular staining, cells were fixed and permeabilized using
Cytofix/Cytoperm (BD PharMingen) according to the manufac-
turer’s instructions. The number of tumor cells (C4.4A +)i nL N
was evaluated by LSR II flow cytometer (Becton Dickinson, San
Jose, CA), and data were analyzed using Flowjo software (Tree
Star, Inc., Ashland, OR).
Immunohistochemistry
Immunohistochemistry was performed on frozen sections using
the AEC Chromogen Kit (Sigma) according to manufacturer’s
protocol. Frozen tissues were sectioned (5–7 mm thickness),
mounted and air-dried. After having been fixed in cold acetone
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hydrogen peroxide for 15 min to inactivate endogenous peroxi-
dase. Slides were then incubated with antibodies against mouse
CD97 (1:200; Abnova), CD44 (1:200, Abcam), CD31(1:200,
Abcam) and VEGF(1:400, Abcam). Positive reactions (rose-red
insoluble precipitates) were developed by incubating the slides with
AEC substrate reagent after treatment with the corresponding
peroxidase-conjugated secondary antibodies. The sections were
then counter-stained with Mayer’s hematoxylin (invitrogen).
Statistical Analysis
Statistical analysis was performed with the SPSS 10.0 software.
Student’s t-test and one-way analysis of variance were used. All
experiments were performed at least in triplicates and were
expressed as mean6SEM with P-values of ,0.05 considered as
statistically significant.
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